Ali Hassan Mushtaq
Overview
Explore the profile of Ali Hassan Mushtaq including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shahzad M, Iqbal Q, Tariq E, Ammad-Ud-Din M, Butt A, Mushtaq A, et al.
Crit Rev Oncol Hematol
. 2024 Feb;
196:104310.
PMID: 38423375
We conducted a systematic review and meta-analysis to evaluate outcomes after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in TP53-mutated myelodysplastic syndromes (MDS). A literature search was performed on PubMed, Cochrane,...
2.
Vriz O, Mushtaq A, Nahid Elshaer A, Shaik A, Landi I, Alzahrani T
Tex Heart Inst J
. 2023 Oct;
50(5).
PMID: 37853912
Background: Data on race-related differences in the clinical outcomes of Takotsubo syndrome are limited, particularly for Black patients. This study aimed to assess whether race and sex may have an...
3.
Mushtaq A, Shafqat A, Salah H, Hashmi S, Muhsen I
Curr Opin Oncol
. 2023 Oct;
35(6):594-600.
PMID: 37820094
Purpose Of Review: This review delves into the potential of artificial intelligence (AI), particularly machine learning (ML), in enhancing graft-versus-host disease (GVHD) risk assessment, diagnosis, and personalized treatment. Recent Findings:...
4.
Vriz O, Alzahrani T, Landi I, Mushtaq A, Shaik A, Nahid Elshaer A
Monaldi Arch Chest Dis
. 2023 Apr;
94(1).
PMID: 37070781
Age and sex differences in Takotsubo syndrome (TTS) are still a matter of debate. The present study aimed to evaluate the difference in cardiovascular (CV) risk factors, CV disease, in-hospital...
5.
Shafqat A, Omer M, Ahmad O, Niaz M, Abdulkader H, Shafqat S, et al.
Front Immunol
. 2022 Dec;
13:1041185.
PMID: 36505475
All currently approved COVID-19 vaccines utilize the spike protein as their immunogen. SARS-CoV-2 variants of concern (VOCs) contain mutations in the spike protein, enabling them to escape infection- and vaccination-induced...
6.
Shahzad M, Chaudhary S, Tariq E, Mushtaq A, Anwar I, Ahmed N, et al.
Leuk Lymphoma
. 2022 Oct;
64(2):273-282.
PMID: 36282773
We systematically evaluated the primary and secondary endpoints used in acute myeloid leukemia (AML) phase III randomized controlled trials (RCTs). We included 238 phase III AML RCTs in the past...
7.
Vriz O, Alsergani H, Nahid Elshaer A, Shaik A, Mushtaq A, Lioncino M, et al.
Monaldi Arch Chest Dis
. 2021 Dec;
92(3).
PMID: 34964577
Hypertrophic cardiomyopathy (HCM) is a group of heterogeneous disorders that are most commonly passed on in a heritable manner. It is a relatively rare disease around the globe, but due...
8.
Akhtar S, Rauf M, Khafaga Y, Al-Kofide A, Elhassan T, Elshenawy M, et al.
BMC Cancer
. 2021 Apr;
21(1):351.
PMID: 33794818
Background: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon variant of Hodgkin lymphoma. There is limited data on treatment, management of refractory and relapsed disease, and long-term outcome. Many registries...
9.
Suleman K, Mushtaq A, Haque E, Badran A, Ajarim D, Elashwah A, et al.
Breast Care (Basel)
. 2021 Mar;
16(1):59-65.
PMID: 33716633
Introduction: Human epidermal growth factor receptor 2 (HER-2) targeted therapy regimens can improve tumor response in HER-2-positive metastatic breast cancer (MBC), with overall survival benefits. Objective: We evaluated the efficacy...
10.
Akhtar S, Rauf M, Al-Kofide A, Elshenawy M, Mushtaq A, Maghfoor I
Hered Cancer Clin Pract
. 2021 Feb;
19(1):17.
PMID: 33563316
Background: Familial clustering of lymphoid and/or hematological malignancies (FHM) provides an opportunity to study the responsible genes. The data is limited in patients with lymphoid and hematological malignancies. Methods: The...